April 23, 2019 10:07 AM EDT

Regeneron's Schleifer: American public companies should fund 'infrastructure bank'; Sherlock closes $49M round for CRISPR diagnostic work

Amber Tong

→ The candid chief of Regeneron Pharmaceuticals $REGN Leonard Schleifer made a provocative suggestion to remedy the burgeoning US infrastructure crisis, citing research that emphasizes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regeneron's Schleifer: American public companies should fund 'infrastructure bank'; Sherlock closes $49M round for CRISPR diagnostic work

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Re­gen­eron's Schleifer: Amer­i­can pub­lic com­pa­nies should fund 'in­fra­struc­ture bank'; Sher­lock clos­es $49M round for CRISPR di­ag­nos­tic work

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Regeneron's Schleifer: American public companies should fund 'infrastructure bank'; Sherlock closes $49M round for CRISPR diagnostic work